Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

Puma Biotechnology

06/08/2026 22:47

Puma Biotechnology Inc PBYI.OQ reported quarterly adjusted earnings of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 12 cents.  The lone analyst forecast for the quarter was for earnings of 4 cents per share. 
Revenue rose 7.8% to $56.50 million from a year ago; analysts expected $53.00 million. 
Puma Biotechnology Inc's reported EPS for the quarter was 16 cents​.
The company reported quarterly net income of $8.2 million.
Puma Biotechnology Inc shares had fallen by 1.5% this quarter and gained 34.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 42.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 59.8% below its last closing price of $7.99
This summary was machine generated from LSEG data August 6 at 09:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.04
0.16
Beat
Mar. 31 2026 
-0.13
-0.07
Beat
Dec. 31 2025 
0.23
0.26
Beat
Sep. 30 2025 
0.05
0.17
Beat